Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients | Zendy

Timothée Klopfenstein | Zendy; Souheil Zayet | Zendy; Anne Lohse | Zendy; Phillippe Selles | Zendy; H. Zahra | Zendy; N’dri Juliette Kadiane-Oussou | Zendy; Lynda Toko | Zendy; PierreYves Royer | Zendy; JeanCharles Balblanc | Zendy; Vincent Gendrin | Zendy; Thierry Conrozier | Zendy

Open Access

Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients

Author(s) -

Timothée Klopfenstein,

Souheil Zayet,

Anne Lohse,

Phillippe Selles,

H. Zahra,

N’dri Juliette Kadiane-Oussou,

Lynda Toko,

PierreYves Royer,

JeanCharles Balblanc,

Vincent Gendrin,

Thierry Conrozier

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.08.024

Subject(s) - tocilizumab , medicine , mechanical ventilation , clinical endpoint , pneumonia , covid-19 , mortality rate , retrospective cohort study , randomized controlled trial , rheumatoid arthritis , disease , infectious disease (medical specialty)

No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research